ESTRO 2025 - Abstract Book

S1709

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

Results: Five patients with LM of the head and neck area were treated. Three patients were male. Median age was 74 years. GTV and CTV volumes were 2,93 and 10,49 cm3, respectively. Median maximum dose, mean dose and dose to the 95% of volume were 55, 51 and 49,5 Gy, respectively. Acute radiation dermatitis was G1 in 4 patients and G3 in 1 patient. Other toxicities included G1-2 conjunctivitis and oral mucositis. After a median of 5 months, complete response was obtained in all patients. One patient recurred after 18 months and underwent salvage surgery. After a median follow-up of 15 months, all patients are alive with no evidence of disease. Conclusion: After tomotherapy-based radiotherapy for LM, response rate and toxicity profile are very favorable. To assure adequate and accurate Tomotherapy treatment delivery, collaboration with dermato-oncologist and delineation of LM subclinical margins are mandatory. References: Ungureanu L, Vasilovici AF, Trufin II, Apostu AP, Halmágyi SR. Lentigo Maligna Treatment-An Update. J Clin Med. 2024 Apr 25;13(9):2527. doi: 10.3390/jcm13092527. Hendrickx A, Cozzio A, Plasswilm L, Panje CM. Radiotherapy for lentigo maligna and lentigo maligna melanoma - a systematic review. Radiat Oncol. 2020 Jul 14;15(1):174. doi: 10.1186/s13014-020-01615-2. Fogarty GB, Hong A, Economides A, Guitera P. Experience with Treating Lentigo Maligna with Definitive Radiotherapy. Dermatol Res Pract. 2018 Jul 15;2018:7439807. doi: 10.1155/2018/7439807. Keywords: Lentigo maligna, Tomotherapy, Multidisciplinarity Digital Poster The impact of radiotherapy and hyperthermia on oncological outcomes in high-risk soft tissue sarcoma Pasquale Trecca 1 , Michele Fiore 1 , Carlo Greco 1 , Gian Marco Petrianni 1 , Gabriele D'Ercole 1 , Sergio Valeri 2 , Edy Ippolito 1 , Bruno Vincenzi 3 , Sara Ramella 1 1 Radiation Oncology, Fondazione Campus Bio-Medico University of Rome, Rome, Italy. 2 General Surgery, Fondazione Campus Bio-Medico University of Rome, rome, Italy. 3 Medical Oncology, Fondazione Campus Bio Medico University of Rome, Rome, Italy Purpose/Objective: The aim of the study is to evaluate the oncological outcomes of patients with high-risk soft tissue sarcoma (STS) of the extremities or trunk who received intensified neoadjuvant treatment combining radiotherapy (RT) and hyperthermia (HT) with or without chemotherapy (CT). 3105